HPV-16 L1 and HPV-18 L1 capsid proteins — Drug Target

All drugs that target HPV-16 L1 and HPV-18 L1 capsid proteins — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Recombinant protein vaccine with adjuvant

Phase 3 pipeline (1)

• HPV-16/18 L1/AS04 · GlaxoSmithKline · Recombinant protein vaccine with adjuvant · Oncology / Immunology
  This vaccine stimulates the immune system to produce antibodies and cellular immunity against HPV-16 and HPV-18 L1 capsid proteins, preventing infection and cervical cancer development.